Cited by 224Advanced Drug Delivery SystemsOcular Infections and TreatmentsGlaucoma and retinal disorders

Principles of pharmacology in the eye

Open access
Awwad, Sahar, Mohamed Ahmed, Abeer H A, Sharma, Garima, Heng, Jacob S, Khaw, Peng T, Brocchini, Steve, Lockwood, Alastair·2017·British Journal of Pharmacology

Abstract

The eye is a highly specialized organ that is subject to a huge range of pathology. Both local and systemic disease may affect different anatomical regions of the eye. The least invasive routes for ocular drug administration are topical (e.g. eye drops) and systemic (e.g. tablets) formulations. Barriers that subserve as protection against pathogen entry also restrict drug permeation. Topically administered drugs often display limited bioavailability due to many physical and biochemical barriers including the pre‐corneal tear film, the structure and biophysiological properties of the cornea, the limited volume that can be accommodated by the cul‐de‐sac, the lacrimal drainage system and reflex tearing. The tissue layers of the cornea and conjunctiva are further key factors that act to restrict drug delivery. Using carriers that enhance viscosity or bind to the ocular surface increases bioavailability. Matching the pH and polarity of drug molecules to the tissue layers allows greater penetration. Drug delivery to the posterior segment is a greater challenge and, currently, the standard route is via intravitreal injection, notwithstanding the risks of endophthalmitis and retinal detachment with frequent injections. Intraocular implants that allow sustained drug release are at different stages of development. Novel exciting therapeutic approaches include methods for promoting transscleral delivery, sustained release devices, nanotechnology and gene therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.14024

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Noninvasive delivery methods offer fewer procedure-related complications and easier administration but reduced bioavailability.

    “Noninvasive delivery methods offer drug delivery with fewer procedure-related complications and easier administration but with reduced bioavailability.35,118”
  • Topical administration is the most used noninvasive method.

    “Of the noninvasive methods, topical administration is the most used.35,118”
  • Topical administration avoids first-pass metabolism and has easy administration, but barriers reduce bioavailability to around 5% or less.

    “This method avoids complications of first-pass metabolism and has the advantage of easy administration, sometimes by the patients themselves. However, barriers, such as the pre-corneal tear film, the structure of the cornea, limited volume, lacrimal drainage system, reflex tearing, and aqueous outflow of the eye, reduce the bioavailability of the product to around 5% or less.35,118,119”
  • Biodegradable and non-biodegradable ocular implants provide a method for sustained release of poorly soluble steroids.

    “Biodegradable and non-biodegradable ocular implants have been used in several drug treatments for conditions such as diabetic macular edema and posterior uveitis, among others, and provide a method for sustained release of poorly soluble steroids.118,126”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 238 · Cited by 224

Authors
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A.
Affiliations
  • Moorfields Eye Hospital NHS Foundation Trust (GB)
  • UCL School of Pharmacy London UK
  • Queen Alexandra Hospital (GB)
Corresponding author
Lockwood, Alastair
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2017-10-10
Volume
174
Issue
23
Pages
4205-4223
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2747197238
Cited by
224
References
238
Citations by year
2026: 22 · 2025: 33 · 2024: 28 · 2023: 34 · 2022: 39 · 2021: 28 · 2020: 20 · 2019: 12 · 2018: 5 · 2017: 1 · 2012: 1
FWCI
1.09
Type
journal article
Language
en
Open access
Locations
  • British Journal of Pharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • National Institute of Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, Moorfields Special Trustees
  • Helen Hamlyn Trust (in memory of Paul Hamlyn), Medical Research Council, Fight for Sight, John Nolan, Kard Bos, Moskoutz, Katz Foundation and Sunrise Foundation
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
Keywords
ocular drug delivery, ocular pharmacology, topical ocular formulations, eye drops, corneal permeation, corneal structure, conjunctiva, bioavailability, lacrimal drainage system, reflex tearing, intravitreal injection, endophthalmitis, retinal detachment, intraocular implants, sustained drug release, transscleral drug delivery, nanotechnology, gene therapy, ocular surface
MeSH terms
Animals, Biological Availability, Delayed-Action Preparations, Drug Carriers, Eye, Eye Diseases, Humans, Ophthalmic Solutions, Drug Design, Drug Delivery Systems, Nanotechnology, Administration, Ophthalmic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review